Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abuse-Deterrent Formulations Exempt From Medicaid Rebates Under Bill

This article was originally published in The Pink Sheet Daily

Executive Summary

Comprehensive opioid addiction legislation is considered by House-Senate conference committee on July 6.

You may also be interested in...

Abuse-Deterrent Exemption From Medicaid Rebates Hinges On FDA Standards

Opioid formulations with abuse-deterrent properties will be exempt from Medicaid price-inflation rebates if they meet FDA standards, Centers for Medicare and Medicaid Services says in guidance to manufacturers.

Medicare Part D Plans To Control Opioid Access With ‘Lock In’ Program

Addiction prevention legislation empowers Medicare drug plans to restrict prescriber, pharmacy access to opioids for ‘at risk’ beneficiaries.

Inter Parfums Hungry For New Brand Licenses With Q1 Sales Up 37%

Inter Parfums is targeting deals with "evergreen-type" brands doing around $50m in annual sales that could benefit from its expertise and extensive distribution network. The firm’s first-quarter sales totaled $198.5m, an increase of 11% compared with 2019 levels and 37% versus the prior-year period.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts